The observed severe clinical outcome of COVID-19 in patients with cardiovascular disease and diabetes could be linked with the decreased expression of ACE2, that make them vulnerable to angiotensin 2 proinflammatory pathway [32]. Here, ACE2 is linked to COVID-19.